EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Evidence-Based Recommendations for the Use of Desidustat in Chronic Kidney Disease

Sourabh Sharma, Bianca Davidson, Dina A Abdellatif, Sanjay Kalra

Journal of the Pakistan Medical Association · 20.04.2026 · 76 (05) · 788-791

DOI: 10.47391/jpma.26-38 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the Pakistan Medical Association, online erschienen am 20.04.2026. Verfasst von Sourabh Sharma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Anemia, Prolyl-Hydroxylase Inhibitors, Hypoxia-Inducible Factor-Proline Dioxygenases. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaemia is a common and clinically significant complication of chronic kidney disease (CKD), contributing to reduced quality of life, cardiovascular morbidity, and increased mortality. Conventional management has relied predominantly on injectable erythropoiesis-stimulating agents (ESAs) and iron supplementation; however, these approaches are associated with limitations including hyporesponsiveness, injection burden, and safety concerns. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have emerged as a novel therapeutic class that stimulates endogenous erythropoietin production while improving iron metabolism. Recent Kidney Disease: Improving Global Outcomes (KDIGO) anaemia guidelines acknowledge HIF-PHIs as therapeutic alternatives in selected patients. This review synthesizes available evidence and provides practical, evidence-based recommendations for the use of desidustat across different stages of CKD. Keywords: Chronic kidney disease, Anemia, Desidustat, HIF-PHI, Erythropoiesis, KDIGO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicAnemiaProlyl-Hydroxylase InhibitorsHypoxia-Inducible Factor-Proline DioxygenasesHumansEvidence-Based MedicineHematinicsErythropoietin

Stichwörter der Autor:innen

Chronic kidney disease, Anemia, Desidustat, HIF-PHI, Erythropoiesis, KDIGO.

Substanzen

HematinicsProlyl-Hydroxylase InhibitorsErythropoietinHypoxia-Inducible Factor-Proline Dioxygenases

Autor:innen und Institutionen

  • Department of Nephrology, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi.
  • Division of Hypertension and Nephrology, Department of Medicine, Groote Schuur Hospital, University of Cape Town, Anzio Road, Observatory, Cape Town, South Africa.
  • Renal Division, Cairo University Hospital, Cairo, Egypt.
  • Department of Endocrinology, Bharti Hospital, Karnal, India; University Centre for Research & Development, Chandigarh University, Mohali, India.

Zitieren

APA

Sharma, S., Davidson, B., Abdellatif, D. A., & Kalra, S. (2026). Evidence-Based Recommendations for the Use of Desidustat in Chronic Kidney Disease. Journal of the Pakistan Medical Association, 76(05), 788-791. https://doi.org/10.47391/jpma.26-38

Vancouver

Sharma S, Davidson B, Abdellatif DA, Kalra S. Evidence-Based Recommendations for the Use of Desidustat in Chronic Kidney Disease. Journal of the Pakistan Medical Association. 2026;76(05):788-791. doi:10.47391/jpma.26-38

BibTeX
@article{Sharma2026,
  author = {Sharma, Sourabh and Davidson, Bianca and Abdellatif, Dina A and Kalra, Sanjay},
  title = {Evidence-Based Recommendations for the Use of Desidustat in Chronic Kidney Disease},
  journal = {Journal of the Pakistan Medical Association},
  year = {2026},
  volume = {76},
  number = {05},
  pages = {788--791},
  doi = {10.47391/jpma.26-38}
}
Kostenlos starten →